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Abstract: Objective: This mini-review provides the rationale and updated progress for ongoing ran-
domized controlled trials assessing fenofibrate and telmisartan efficacy to limit abdominal aortic aneu-
rysm (AAA) growth. 
Methods/Results: There remains an urgent need to identify a drug therapy that will limit AAA growth. 
Data from preclinical and human studies indicate that fenofibrate and telmisartan have the potential to 
slow aortic destruction. Fenofibrate has been shown to reduce serum and tissue levels of the pro-
inflammatory protein osteopontin, as well as reducing macrophage recruitment to the aortic wall, both of 
which are integral processes in the development and progression of AAAs. Telmisartan acts via blockade 
of the angiotensin II receptor, type 1, and also as a peroxisome proliferator-activated receptor gamma 
agonist. In turn, this inhibits the production of a range of biomarkers associated with AAA progression, 
including transforming growth factor-beta one, osteoprotegerin, osteopontin and matrix metalloprotein-
ase-9. Based on these findings, there are currently three randomized controlled trials assessing both fen-
ofibrate and telmisartan as potential interventions to limit aneurysm growth in AAA patients.  
Conclusion: Fenofibrate and telmisartan have potential as repurposed medications to limit AAA 
growth, and randomized trials for further assessment in AAA patients are ongoing. 
Keywords: Abdominal aortic aneurysm, telmisartan, fenofibrate, osteopontin, angiotensin, clinical trial. 
INTRODUCTION 
1. PRESENT MANAGEMENT AND SIGNIFICANCE 
OF AAA 
Abdominal aortic aneurysm (AAA) is a progressive de-
structive process of the main abdominal artery, with a preva-
lence of 2-5% in men and 1% in women aged over 65 years 
[1]. In 2010, the estimated global prevalence rate was 2,275 
per 100,000 in individuals aged 75-79 years [2]. The global 
death rate due to AAA increased from 2.49 to 2.78 per 
100,000 between 1990 and 2010, with the highest mean 
death rate occurring in Australasia [3]. The present manage-
ment options for AAA are surgical repair (open or endovas-
cular), or follow-up by imaging at intervals, i.e. conservative 
treatment with no therapeutic intervention [4]. In view of the 
increasing importance of AAA as a cause of mortality, ultra-
sound screening has been introduced in the United States, 
United Kingdom and Sweden [5]. Such screening of at risk 
individuals, either on a population basis or as arranged selec-
tively by practitioners usually identifies AAAs of small size, 
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with 90% measuring less than 50mm [6]. Large randomized 
trials have failed to provide evidence that early elective sur-
gical repair of patients with small AAAs (40-54mm) reduces 
mortality [7-10]. In summary, surgery does not appear to 
offer any solution for the increasing number of patients with 
small AAAs.  
2. THE URGENT NEED FOR AN EFFECTIVE DRUG 
THERAPY FOR SMALL AAA 
Due to continued aortic expansion in individuals with 
small AAAs, up to 70% of patients will ultimately require 
surgical repair [7, 10]. Thus, there is a need to identify medi-
cations that can slow aortic destruction. Such drug therapy 
could be used in patients with small AAAs to reduce the 
number later requiring surgery, in those unsuitable for AAA 
repair, and to reduce the need for secondary intervention in 
those previously treated surgically [11]. Although advisable, 
there is presently no evidence that control of atherosclerotic 
risk factors alone reduces AAA progression [12]. There have 
been relatively few randomized controlled trials completed 
to identify a drug therapy that will slow AAA growth, with 
no large trial demonstrating the benefit of any tested agent 
[13-18]. There are however a number of such trials ongoing 
and these have recently been reviewed in detail elsewhere 
[1]. To successfully be investigated in a randomized trial, a 
1873-5592/18 $58.00+.00 © 2018 Bentham Science Publishers 
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potential medication requires evidence to support its benefit, 
a good safety profile, a large proportion of individuals with 
AAAs in whom the medication is not already indicated, and 
a likelihood of good compliance. The remainder of this re-
view will focus on two agents that fit those criteria, namely 
fenofibrate and telmisartan.  
3. RATIONALE FOR A DRUG TRIAL OF FENOFI-
BRATE IN PARTICIPANTS WITH SMALL AAAs 
Pre-clinical studies have demonstrated that the perox-
isome proliferator-activated receptor alpha (PPARα) agonist, 
fenofibrate, reduces the development of experimental AAAs 
[19, 20]. Administration of fenofibrate in a mouse model 
inhibited AAA progression which was associated with a re-
duction of the pro-inflammatory protein osteopontin (OPN), 
and reduced recruitment of macrophages to the aortic wall 
[19]. OPN is a phosphorylated acidic glycoprotein which 
was originally identified in bone and shown to facilitate os-
teoclast binding to mineralized matrix [21]. Subsequently, 
OPN has been shown to be widely expressed in the arterial 
system and implicated in promoting inflammation, proteoly-
sis and atherosclerosis, all of which are integral processes in 
AAA development and progression [22-27]. OPN deficiency 
has been shown to protect against AAA development in mice 
[28]. The ability of OPN to promote macrophage accumula-
tion within the aorta appears critical in the development and 
progression of AAA in experimental models [28, 29].  
To assess the relevance of OPN to human AAA, we ex-
amined two cohorts: a) 466 men that took part in a commu-
nity ultrasound screening study in Western Australia (WA), 
of whom 233 had an AAA; and b) 199 patients referred for 
aortic imaging at a vascular centre in Queensland, of who 
132 had an AAA. The mean (±SD) serum OPN concentra-
tions were 77±32 ng/ml and 66±29 ng/ml in men from WA 
who did and did not have AAAs, respectively, p<0.001 [30]. 
The mean (±SD) serum OPN concentrations were 73±44 
ng/ml and 59±44 ng/ml in patients from Queensland who did 
and did not have AAAs, respectively, p=0.001 [30]. Serum 
OPN concentration was independently associated with AAA 
after adjusting for other risk factors in both cohorts. 198 of 
the men from WA underwent repeat imaging of their AAA 
for at least 3 years with a mean (±SD) increase in aortic di-
ameter of 3.5±3.3 mm. Serum OPN was independently asso-
ciated with AAA growth after adjusting for other risk fac-
tors. In patients who underwent open AAA repair, OPN ex-
pression was assessed in AAA biopsies by real time PCR 
and immunohistochemistry. Expression of mRNA encoding 
OPN and the 65 kD intact OPN protein were increased in 
AAA biopsies when compared to samples of normal ab-
dominal aortas from age-matched organ donors. Further-
more, OPN staining was demonstrated within areas of calci-
fication and macrophage infiltration in human AAA biopsies 
[30]. The upregulation of OPN in human AAA biopsies has 
been confirmed by other investigators [31, 32]. These data 
suggest that: a) OPN is highly associated with human AAA 
presence and progression; b) serum OPN may be a useful 
biomarker for AAA pathology; and c) OPN may promote 
AAA by stimulating macrophage based aortic destruction.  
Macrophages appear to be a primary target of the detri-
mental effects of OPN [21, 22, 33, 34]. Macrophages are 
implicated in aortic destruction as a result of the production 
of a range of proteolytic enzymes such as matrix metallopro-
teinases (MMPs) [11]. Previous in vitro studies demonstrate 
that PPARα ligands downregulate OPN expression in human 
macrophages by rapidly inhibiting transcription of the OPN 
gene [35]. Fibrates are well known PPARα agonists in clini-
cal use for the treatment of hypertriglyceridemia [36]. Previ-
ous rodent studies demonstrate that fenofibrate downregu-
lates OPN in left ventricle hypertrophy and dysfunctional 
renal cells [37, 38]. Furthermore, following four weeks of 
bezafibrate treatment in diabetic patients, a 23% reduction in 
circulating concentrations of OPN was observed [35]. To-
gether, these data support the action of fibrates to negatively 
regulate OPN in vitro and in vivo.  
In view of the ability of fibrates to downregulate OPN, 
and the significant evidence implicating OPN in AAA 
pathogenesis, we hypothesized that fenofibrate would inhibit 
aortic expression of OPN thus limiting AAA progression. As 
an initial test of this hypothesis, we examined the effect of 
fenofibrate in two established experimental models of AAA 
[19, 20]. First, the effect of fenofibrate (100mg/kg/d) versus 
control was examined in apolipoprotein E deficient (ApoE
-/-
) 
mice receiving angiotensin II (AngII) infusion to induce 
AAA formation [19]. Fenofibrate markedly reduced aortic 
concentrations of OPN and associated macrophage infiltra-
tion. The median and interquartile range for aortic OPN con-
centration in mice administered fenofibrate or control was 
126 (35-729) and 3198 (382-11138) pg/mg of protein, re-
spectively; p=0.006 [19]. The median and interquartile range 
for CD68 (macrophage) staining within aortas of fenofibrate 
and control mice was 4.0 (2.2-6.1) % and 13.2 (8.4-20.0) %, 
respectively; p<0.001 [19]. Fenofibrate inhibited AAA pro-
gression with the maximum aortic diameter reduced from a 
mean (±SD) of 2.10±0.14 mm in control mice to 1.51±0.13 
mm in mice receiving fenofibrate; p=0.001 [19]. To assess 
the reproducibility of this finding, we examined the effect of 
fenofibrate in a second mouse model deficient in low density 
lipoprotein (LDL) receptor (Ldlr
-/-
), in which AAA was in-
duced with AngII infusion [20]. Mean (±SD) aortic diame-
ters were 1.06±0.06 mm and 1.25±0.05 mm in mice receiv-
ing fenofibrate (100mg/kg/d) and control for 4 weeks, re-
spectively; p=0.002 [20]. These data demonstrate the effi-
cacy of fenofibrate in downregulating aortic expression of 
OPN and associated macrophage infiltration, and in limiting 
AAA progression.  
Fenofibrate has other effects that suggest it is likely to limit 
aortic aneurysm, including: 
a) Beneficial effects on serum proteins: Previous studies 
indicate that short term fenofibrate therapy reduces LDL 
and triglyceride serum concentrations, and increases high 
density lipoprotein (HDL) [39-41]. High serum HDL and 
low serum triglyceride levels have been negatively asso-
ciated with AAA [42-44]. In addition, HDL has been 
demonstrated to have a range of anti-inflammatory ef-
fects, and thus the ability of fenofibrate to raise HDL and 
lower triglyceride could inhibit aortic inflammation and 
act as an additional mechanism to stabilize AAAs;  
b) Reduced visceral fat adipokine release: Obesity and vis-
ceral fat accumulation are risk factors for AAA, with 
previous data indicating that circulating adipokines, in 
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particular high serum resistin, are associated with human 
AAA [45]. Visceral adipose tissue has been suggested to 
be an important source of pro-inflammatory adipokines, 
such as resistin, and has also been implicated in promot-
ing aortic inflammation in animal models of AAA [46, 
47]. Previous studies suggest that fenofibrate can down-
regulate resistin production from visceral adipose tissue 
[46, 47]. The ability of fenofibrate to inhibit resistin pro-
duction from periaortic adipose tissue could act as a fur-
ther mechanism to inhibit inflammation and associated 
aortic destruction;  
c) Reduced MMP-9 activity: MMP-9 has been implicated in 
AAA [42, 48]. MMPs, including MMP-9 are important 
not only in direct extracellular matrix (ECM) degrada-
tion, but also in activating pro-inflammatory cytokines. 
Furthermore, MMPs have been shown to cleave OPN to 
a more active form [49, 50]. Data from in vitro studies 
suggest that fenofibrate inhibits MMP-9 production by 
vascular cells relevant to AAA progression, including 
macrophages and endothelial cells [51-53]. The 
downregulation of MMP-9 by fenofibrate would be 
expected to inhibit aortic destruction, in addition to 
limiting activation of important pro-inflammatory 
cytokines, such as OPN. Overall, these data suggest that 
fenofibrate can inhibit key pathological mechanisms 
involved in human AAA progression, as outlined in Fig. 
(1). 
 
 
Fig. (1). Schematic illustrating the proposed mechanism by which 
fenofibrate reduces AAA progression. 
4. FENOFIBRATE IN THE MANAGEMENT OF AB-
DOMINAL AORTIC ANEURYSM (FAME) AND 
FAME-2 
FAME and FAME-2 are multi-centre, randomized, dou-
ble-blind, placebo controlled trials which have recently been 
described in detail elsewhere [54, 55]. FAME looks to exam-
ine the effect of 145mg of fenofibrate taken daily for a 
minimum of 2 weeks in 42 participants scheduled for an 
elective open AAA repair. The primary aims are to investi-
gate whether fenofibrate will reduce the relative number of 
AAA wall macrophages, reduce the relative concentration of 
AAA wall OPN, and reduce serum concentrations of OPN. 
The effect of fenofibrate on secondary parameters, including 
inflammatory cell number; MMPs and pro-inflammatory 
cytokines within the AAA wall, periaortic fat and intramural 
thrombus; and circulating concentrations of AAA biomark-
ers including osteoprotegerin (OPG), resistin, D-dimer and 
fasting lipids will also be assessed. FAME-2 is a longer trial 
examining 24 weeks treatment with 145mg fenofibrate on 
key pathological markers of AAA in 140 participants with 
small AAAs. The primary aim is to investigate whether fen-
ofibrate will reduce serum OPN concentration. Secondary 
aims include examination of the effect of fenofibrate on se-
rum levels of resistin, lipids, MMPs and pro-inflammatory 
cytokines; circulating concentrations of AAA biomarkers; 
and AAA diameter assessed by ultrasound. Recruitment and 
follow-up for the FAME and FAME-2 trials is now complete 
with analysis underway.  
5. RATIONALE FOR A DRUG TRIAL OF 
TELMISARTAN IN PARTICIPANTS WITH SMALL 
AAAs 
AngII plays a central role in the regulation of blood pres-
sure and electrolyte homeostasis, and is also capable of in-
ducing an inflammatory response in the vascular wall [56]. 
In rodents, AngII stimulates the angiotensin II receptor, type 
1 (AT1) to promote a series of molecular changes leading to 
AAA formation [57]. AngII infusion has been demonstrated 
to stimulate aneurysm formation in mice [11, 28, 57-59], 
which particularly affects the suprarenal aorta. The incidence 
of AAA development induced by AngII is greater in mice 
with similar risk factors to those associated with human 
AAA, such as male sex, atherosclerosis and dyslipidaemia. 
In these models, AAA induced by AngII is associated with 
increased aortic expression of pro-inflammatory cytokines, 
such as OPG, OPN and transforming growth factor-beta one 
(TGF-β1), increased macrophage recruitment, and up-
regulation of MMP-9 [57]. Experimental AAA is inhibited 
by activation of the nuclear receptor PPARγ. In mice admin-
istered PPARγ agonist over 28 days, the mean (±SD) supra-
renal aortic diameter was reduced from 2.1±0.1 mm to 
1.6±0.1 mm; p=0.01 [57]. PPARγ activation inhibited the 
ability of AngII to up-regulate OPG, OPN, MMP-9 and 
TGF-β1 [57]. 
OPG has previously been shown to stimulate an aneu-
rysm phenotype in endothelial cells, vascular smooth muscle 
cells (VSMCs) and monocytes by promoting inflammation, 
VSMC apoptosis and release of MMP-9 [60, 61]. Further-
more, OPN- and OPG-deficient mice are relatively resistant 
to AAA induction by AngII [28]. OPG and TGF-β1 stimu-
late up-regulation of AT1, leading to further downregulation 
of PPARγ and promotion of macrophage recruitment, matrix 
degradation and AAA formation [57]. Together these data 
provide a pathway by which AngII, TGF-β1, OPG, OPN and 
MMP-9 collaborate in stimulating AAA. The pathway can be 
interrupted using AT1 blockers and PPARγ agonists, (Fig. 
2). AT1 blockade completely abolishes the development of 
AAA in AngII-infused ApoE
-/- 
mice [59]. Thus, AT1 is an 
attractive target for inhibiting the ability of AngII to promote 
AAA [11, 28, 58, 59]. Studies conducted using cultured hu-
man and murine cells, in addition to explants of human AAA 
biopsies, provide evidence that AngII binds to AT1 to pro-
mote downregulation of PPARγ by a TGF-β1 dependent 
mechanism [57]. In turn, AT1 blockade and PPARγ activa-
Fenofibrate 
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tion inhibits OPG and MMP-9 secretion by AAA explants 
[61]. 
Numerous additional findings support the importance of 
the AngII promoted pathological pathway. The concentra-
tion of a variety of AngII producing enzymes, including 
angiotensin converting enzyme (ACE), are increased in 
human AAA biopsies, and inhibiting these enzymes an-
tagonizes the development of AAA in animal models [62-
66]. Elevated MMP-9 has been coincidentally linked with 
human AAA, and deficiency of MMP-9 inhibits AAA de-
velopment in mice [11, 42, 48]. Serum concentrations of 
OPG and OPN are elevated in participants with AAA, and 
are positively associated with the rate of AAA progression 
after adjusting for other risk factors [61, 66]. An interaction 
between AngII, TGF-β1, OPG and OPN in promoting car-
dinal features of AAA, such as inflammation and ECM 
destruction, is confirmed in multiple in vitro and animal 
studies [67-70]. Importantly, AT1 blockade has been dem-
onstrated to inhibit AAA development in three independent 
animal models of AAA [59, 69, 71]. Studies by other inves-
tigators also confirm that stimulation of AT1 promotes in-
activation of PPARγ [72]. The PPARγ ligand rosiglitazone 
inhibits AAA formation and rupture in another mouse 
model [73]. 
Based on the data above, a medication that blocks the 
AT1 would appear to be an ideal therapy to reduce AAA 
progression. This approach is preferable to ACE inhibition 
for a number of reasons. For instance, unlike AT1 blockade, 
ACE inhibition will only indirectly inhibit the AngII path-
way, and since a number of non-ACE AngII producing en-
zymes have been identified in human AAA biopsies [62, 66], 
it would only be expected to partially inhibit the progression 
of AAA. Also, much of the blood pressure lowering effect of 
ACE inhibitors appears to be due to increased circulating 
kinins [74]. We have previously reported that stimulation of 
the B2 kinin receptor promotes AAA progression and rup-
ture in mice [75]. Telmisartan is a potent long acting AT1 
blocker and also acts as a PPARγ agonist [76, 77]. Previous 
data has emphasized the potential value of PPARγ activation 
in limiting AAA progression [19, 73]. Telmisartan has PPAR 
agonist activity that is significantly greater than other AT1 
blockers, in addition to its AT1 blocker actions [77, 78]. 
Based on this data, telmisartan would be expected to be an 
ideal drug to limit AAA growth.  
6. TELMISARTAN IN THE MANAGEMENT OF AB-
DOMINAL AORTIC ANEURYSM (TEDY) 
TEDY is an international multi-centre, randomized, dou-
ble-blind placebo controlled trial. Participants with small 
AAAs will be randomized to either 40mg of telmisartan or 
identical placebo, daily for 24 months. The primary aim is to 
investigate whether telmisartan reduces AAA growth as-
sessed by either: a) maximum diameter on ultrasound; b) 
maximum orthogonal diameter on computed tomography 
angiography (CTA); or c) maximum infrarenal aortic volume 
on CTA. The secondary aims are to investigate how treat-
ment with telmisartan effects: a) circulating biomarkers for 
AAA progression (OPG, OPN, MMP-9, TGF-β1 and plasma 
D-dimer); b) health-related quality of life; c) blood pressure; 
and c) requirement for AAA surgery. The TEDY study pro-
tocol has been published previously and is beyond the scope 
of this review [79]. Recruitment for TEDY has now con-
cluded and the trial is expected to report in approximately 18 
months. 
CONCLUSION 
There is no current drug therapy for AAA which has been 
shown to effectively limit AAA growth [20]. This mini-
review describes the rationale for current trials examining 
the potential of the repurposed medications fenofibrate and 
telmisartan which are expected to report within the next 18 
months. It is hoped these trials will identify a novel medica-
tion for patients with small AAAs. 
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